Pennsylvania Medicaid spending on GLP-1 drugs

How much did Pennsylvania Medicaid spend on GLP-1 drugs like Ozempic and Mounjaro in 2025?

Pharmacies were reimbursed at least $951.4 million for GLP-1 drugs paid through Pennsylvania Medicaid in 2025, across at least 844,001 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 107 rows of 366, so these figures are floors.

Pharmacies were reimbursed at least $69.4 million for GLP-1 drugs paid through Pennsylvania Medicaid in 2026 (quarter 1 only, as posted so far), across at least 68,534 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 27 rows of 85, so these figures are floors.

By year and ingredient

2020at least $7,348,170No dataat least $27,691,295at least $87,959,080at least $1,902,108Suppressedat least $198,497at least $359,632at least $125,458,782
2021at least $30,293,851No dataat least $25,028,545at least $121,142,098at least $471,354Suppressedat least $301,827at least $340,659at least $177,578,334
2022at least $20,827,949at least $591,070$25,973,924at least $191,264,132at least $322,537No data$372,270at least $297,810at least $239,649,692
2023at least $124,136,453at least $11,137,470at least $37,787,300at least $262,624,015at least $177,876No data$384,657at least $254,213at least $436,501,984
2024at least $373,440,338at least $67,901,257at least $13,793,916at least $172,104,036at least $88,525No dataat least $263,013$159,131at least $627,750,216
2025at least $573,191,621at least $261,402,320at least $3,949,945at least $112,578,665at least $11,912No dataat least $160,459$110,896at least $951,405,819
2026 (Q1)at least $43,851,528at least $10,524,852at least $284,584at least $14,683,536No dataNo data$21,241$18,053at least $69,383,793

By product, 2025

Ozempicat least $240,561,797at least 234,7465 of 34
Rybelsusat least $3,176,627at least 2,9918 of 23
Wegovy$329,453,197247,3310 of 40
Mounjaroat least $39,445,316at least 35,98213 of 61
Zepboundat least $221,957,004at least 207,26133 of 83
Liraglutide (generic name listing)at least $705,627at least 1,13421 of 41
Saxendaat least $1,957,317at least 1,5423 of 7
Victozaat least $1,287,001at least 1,8775 of 13
Trulicityat least $112,578,665at least 110,86412 of 48
Bydureonat least $11,912at least 151 of 2
ByettaSuppressedSuppressed1 of 1
Exenatide (generic name listing)SuppressedSuppressed2 of 2
Soliquaat least $160,459at least 1763 of 7
Xultophy$110,896820 of 4

By quarter, 2025

Q1 2025at least $212,324,166at least 188,19024 of 90
Q2 2025at least $234,385,701at least 207,50128 of 91
Q3 2025at least $249,736,416at least 222,07026 of 91
Q4 2025at least $254,959,536at least 226,24029 of 94

By quarter, 2026 (posted so far)

Q1 2026at least $69,383,793at least 68,53427 of 85

The amounts are CMS’s “Total Amount Reimbursed” field. CMS’s data dictionary for State Drug Utilization Data says of it:

“This total is not reduced or affected by Medicaid rebates paid to the state. This amount represents both the Federal and State Reimbursement and is inclusive of dispensing fees.”

Its prescription count is “The number of prescriptions reimbursed (by the Medicaid Program ONLY) to pharmacists for the (11-digit NDC) drug for the period covered.”

CMS suppresses some rows (its “Suppression Used” field is true and the counts and amounts are left blank). Here a suppressed row is never counted as zero: a figure that includes suppressed rows is shown as “at least” the sum of the rows CMS did publish, and a figure where every row is suppressed is shown as “Suppressed.” The “Rows suppressed” column gives the count. Where many rows are suppressed, the published sum can be well below the full amount, so floors for different states are not directly comparable.

Fee-for-service and managed care rows are added together. Other states: Medicare and Medicaid spending on GLP-1 drugs.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.